{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T06:17:11Z","timestamp":1791526631928,"version":"4.3.4"},"reference-count":58,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004484","name":"Tehran University of Medical Sciences and Health Services","doi-asserted-by":"publisher","award":["36431"],"award-info":[{"award-number":["36431"]}],"id":[{"id":"10.13039\/501100004484","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Patients with schizophrenia can generally manifest a broad variety of primary negative symptoms. The current study aimed to assess the efficacy and tolerability of resveratrol add-on therapy in the treatment of negative symptoms in patients with stable schizophrenia.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In a randomized, double-blind, and placebo-controlled setting, schizophrenia patients were assigned to receive either 200 mg\/d resveratrol or matched placebo in addition to a stable dose of risperidone for 8 weeks. Patients were assessed using the positive and negative syndrome scale, the extrapyramidal symptom rating scale, and Hamilton Depression Rating Scale over the trial period. The primary outcome was considered as the change in positive and negative subscale score from baseline to week 8 between the treatment arms.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total 52 patients completed the trial (26 in each arm). Baseline characteristics of both groups were statistically similar (P \u2009&amp;gt;\u2009.05). Despite the statistically similar behavior of positive symptoms between the groups across time (Greenhouse-Geisser corrected: F\u2009=\u20091.76, df\u2009=\u20091.88, P\u2009=\u2009.180), the resveratrol group demonstrated greater improvement in negative, general psychopathology, and total scores (Greenhouse-Geisser corrected: F\u2009=\u200912.25, df\u2009=\u20092.04, P\u2009&amp;lt;\u2009.001; F\u2009=\u20095.42, df\u2009=\u20091.56, P\u2009=\u2009.011; F\u2009=\u20097.64, df\u2009=\u20091.48, P\u2009=\u2009.003). HDRS scores and its changes, ESRS score, and frequency of other complications were not significantly different between resveratrol and placebo groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Adding resveratrol to risperidone can exhibit remarkable efficacy and safety in terms of management of schizophrenia-related negative symptoms.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ijnp\/pyaa006","type":"journal-article","created":{"date-parts":[[2020,11,28]],"date-time":"2020-11-28T12:11:02Z","timestamp":1606565462000},"page":"775-782","source":"Crossref","is-referenced-by-count":31,"title":["Resveratrol Adjunct Therapy for Negative Symptoms in Patients With Stable Schizophrenia: A Double-Blind, Randomized Placebo-Controlled Trial"],"prefix":"10.1093","volume":"23","author":[{"given":"Areoo","family":"Samaei","sequence":"first","affiliation":[{"name":"Psychiatric Research Center, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamyar","family":"Moradi","sequence":"additional","affiliation":[{"name":"Psychiatric Research Center, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayna","family":"Bagheri","sequence":"additional","affiliation":[{"name":"Psychiatric Research Center, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2745-5032","authenticated-orcid":false,"given":"Amir","family":"Ashraf-Ganjouei","sequence":"additional","affiliation":[{"name":"Psychiatric Research Center, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Alikhani","sequence":"additional","affiliation":[{"name":"Psychosis Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiedeh Bentolhoda","family":"Mousavi","sequence":"additional","affiliation":[{"name":"Psychosis Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzin","family":"Rezaei","sequence":"additional","affiliation":[{"name":"Qods Hospital, Kurdistan University of Medical Sciences, Sanandaj, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahin","family":"Akhondzadeh","sequence":"additional","affiliation":[{"name":"Psychiatric Research Center, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,12,1]]},"reference":[{"key":"2020122903594710500_CIT0001","first-page":"295","article-title":"The 5-HT hypothesis of schizophrenia","volume":"4","author":"Akhondzadeh","year":"2001","journal-title":"Idrugs"},{"key":"2020122903594710500_CIT0002","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.schres.2006.11.016","article-title":"Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial","volume":"90","author":"Akhondzadeh","year":"2007","journal-title":"Schizophr Res"},{"key":"2020122903594710500_CIT0003","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.biopsych.2008.03.004","article-title":"N-acetyl cysteine as a glutathione precursor for schizophrenia\u2013a double-blind, randomized, placebo-controlled trial","volume":"64","author":"Berk","year":"2008","journal-title":"Biol Psychiatry"},{"key":"2020122903594710500_CIT0004","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.neubiorev.2010.10.008","article-title":"Oxidative stress in schizophrenia: an integrated approach","volume":"35","author":"Bitanihirwe","year":"2011","journal-title":"Neurosci Biobehav Rev"},{"key":"2020122903594710500_CIT0005","first-page":"47","article-title":"The role of dopamine in schizophrenia from a neurobiological and evolutionary perspective: old fashioned, but still in vogue","volume":"5","author":"Brisch","year":"2014","journal-title":"Front Psychiatry"},{"key":"2020122903594710500_CIT0006","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/S0006-3223(99)00117-1","article-title":"Neurotransmitter interactions in schizophrenia\u2013therapeutic implications","volume":"46","author":"Carlsson","year":"1999","journal-title":"Biol Psychiatry"},{"key":"2020122903594710500_CIT0007","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/ane.12511","article-title":"Resveratrol improves delayed r-tPA treatment outcome by reducing MMPs","volume":"134","author":"Chen","year":"2016","journal-title":"Acta Neurol Scand"},{"key":"2020122903594710500_CIT0008","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.schres.2005.02.013","article-title":"Manual for the Extrapyramidal Symptom Rating Scale (ESRS)","volume":"76","author":"Chouinard","year":"2005","journal-title":"Schizophr Res"},{"key":"2020122903594710500_CIT0009","doi-asserted-by":"crossref","first-page":"777","DOI":"10.2147\/NDT.S43404","article-title":"Addressing the unmet needs of patients with persistent negative symptoms of schizophrenia: emerging pharmacological treatment options","volume":"10","author":"Chue","year":"2014","journal-title":"Neuropsychiatr Dis Treat"},{"key":"2020122903594710500_CIT0010","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.abb.2010.05.003","article-title":"Regulation of SIRT1 in cellular functions: role of polyphenols","volume":"501","author":"Chung","year":"2010","journal-title":"Arch Biochem Biophys"},{"key":"2020122903594710500_CIT0011","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s00213-003-1709-2","article-title":"The NMDA receptor glycine modulatory site: a therapeutic target for improving cognition and reducing negative symptoms in schizophrenia","volume":"174","author":"Coyle","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"2020122903594710500_CIT0012","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1196\/annals.1300.020","article-title":"Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia","volume":"1003","author":"Coyle","year":"2003","journal-title":"Ann N Y Acad Sci"},{"key":"2020122903594710500_CIT0013","volume-title":"DSM-5","author":"Diagnostic and Statistical Manual of Mental Disorders","year":"2013","edition":"5th ed."},{"key":"2020122903594710500_CIT0014","first-page":"121","article-title":"The revised dopamine hypothesis of schizophrenia: evidence from pharmacological MRI studies with atypical antipsychotic medication","volume":"41","author":"da Silva Alves","year":"2008","journal-title":"Psychopharmacol Bull"},{"key":"2020122903594710500_CIT0015","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3109\/03602532.2012.700715","article-title":"Drug interaction potential of resveratrol","volume":"44","author":"Detampel","year":"2012","journal-title":"Drug Metab Rev"},{"key":"2020122903594710500_CIT0016","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/schbul\/sbj055","article-title":"Treatment of schizophrenia negative symptoms: future prospects","volume":"32","author":"Erhart","year":"2006","journal-title":"Schizophr Bull"},{"key":"2020122903594710500_CIT0017","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S0006-2952(01)00775-4","article-title":"Immunomodulatory activity of resveratrol: suppression of lymphocyte proliferation, development of cell-mediated cytotoxicity, and cytokine production","volume":"62","author":"Gao","year":"2001","journal-title":"Biochem Pharmacol"},{"key":"2020122903594710500_CIT0018","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1055\/s-0042-116159","article-title":"Crocus sativus L. versus citalopram in the treatment of major depressive disorder with anxious distress: a double-blind, controlled clinical trial","volume":"50","author":"Ghajar","year":"2017","journal-title":"Pharmacopsychiatry"},{"key":"2020122903594710500_CIT0019","doi-asserted-by":"crossref","first-page":"e2662","DOI":"10.1002\/hup.2662","article-title":"Citicoline (CDP-choline) add-on therapy to risperidone for treatment of negative symptoms in patients with stable schizophrenia: a double-blind, randomized placebo-controlled trial","volume":"33","author":"Ghajar","year":"2018","journal-title":"Hum Psychopharmacol"},{"key":"2020122903594710500_CIT0020","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.psychres.2018.02.012","article-title":"L-carnosine as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: a double-blind, randomized placebo-controlled trial","volume":"262","author":"Ghajar","year":"2018","journal-title":"Psychiatry Res"},{"key":"2020122903594710500_CIT0021","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1007\/s11130-015-0518-1","article-title":"Functional properties of grape and wine polyphenols","volume":"70","author":"Giovinazzo","year":"2015","journal-title":"Plant Foods Hum Nutr"},{"key":"2020122903594710500_CIT0022","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2020122903594710500_CIT0023","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/schbul\/sbz041","article-title":"Societal costs of schizophrenia in Denmark: a nationwide matched controlled study of patients and spouses before and after initial diagnosis","volume":"46","author":"Hastrup","year":"2020","journal-title":"Schizophr Bull"},{"key":"2020122903594710500_CIT0024","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/schbul\/sbp006","article-title":"The dopamine hypothesis of schizophrenia: version III\u2013the final common pathway","volume":"35","author":"Howes","year":"2009","journal-title":"Schizophr Bull"},{"key":"2020122903594710500_CIT0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbr.2014.03.052","article-title":"Antidepressant effects of resveratrol in an animal model of depression","volume":"268","author":"Hurley","year":"2014","journal-title":"Behav Brain Res"},{"key":"2020122903594710500_CIT0026","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/hup.2517","article-title":"The effects of pioglitazone adjuvant therapy on negative symptoms of patients with chronic schizophrenia: a double-blind and placebo-controlled trial","volume":"31","author":"Iranpour","year":"2016","journal-title":"Hum Psychopharmacol"},{"key":"2020122903594710500_CIT0027","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.2337\/db11-1498","article-title":"Resveratrol attenuates obesity-associated peripheral and central inflammation and improves memory deficit in mice fed a high-fat diet","volume":"61","author":"Jeon","year":"2012","journal-title":"Diabetes"},{"key":"2020122903594710500_CIT0028","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.2337\/db11-1498","article-title":"Resveratrol attenuates obesity-associated peripheral and central inflammation and improves memory deficit in mice fed a high-fat diet","volume":"61","author":"Jeon","year":"2012","journal-title":"Diabetes"},{"key":"2020122903594710500_CIT0029","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2174\/157015911795017353","article-title":"Neuroprotective effect of resveratrol against methamphetamine-induced dopaminergic apoptotic cell death in a cell culture model of neurotoxicity","volume":"9","author":"Kanthasamy","year":"2011","journal-title":"Curr Neuropharmacol"},{"key":"2020122903594710500_CIT0030","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull"},{"key":"2020122903594710500_CIT0031","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.3945\/ajcn.2009.28641","article-title":"Effects of resveratrol on cerebral blood flow variables and cognitive performance in humans: a double-blind, placebo-controlled, crossover investigation","volume":"91","author":"Kennedy","year":"2010","journal-title":"Am J Clin Nutr"},{"key":"2020122903594710500_CIT0032","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.4088\/JCP.12m07706","article-title":"Oral scopolamine augmentation in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled study","volume":"73","author":"Khajavi","year":"2012","journal-title":"J Clin Psychiatry"},{"key":"2020122903594710500_CIT0033","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/schbul\/sbj053","article-title":"The NIMH-MATRICS consensus statement on negative symptoms","volume":"32","author":"Kirkpatrick","year":"2006","journal-title":"Schizophr Bull"},{"key":"2020122903594710500_CIT0034","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1093\/schbul\/sbt141","article-title":"Inflammation and schizophrenia","volume":"39","author":"Kirkpatrick","year":"2013","journal-title":"Schizophr Bull"},{"key":"2020122903594710500_CIT0035","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s11011-016-9927-6","article-title":"Neurobehavioural evaluation of resveratrol in murine models of anxiety and schizophrenia","volume":"32","author":"Magaji","year":"2017","journal-title":"Metab Brain Dis"},{"key":"2020122903594710500_CIT0036","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1440-1819.2012.02354.x","article-title":"Cytokines in schizophrenia: possible role of anti-inflammatory medications in clinical and preclinical stages","volume":"66","author":"Mansur","year":"2012","journal-title":"Psychiatry Clin Neurosci"},{"key":"2020122903594710500_CIT0037","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.pharmthera.2011.06.003","article-title":"Inflammatory processes in schizophrenia: a promising neuroimmunological target for the treatment of negative\/cognitive symptoms and beyond","volume":"132","author":"Meyer","year":"2011","journal-title":"Pharmacol Ther"},{"key":"2020122903594710500_CIT0038","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.euroneuro.2014.03.008","article-title":"Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment","volume":"24","author":"Millan","year":"2014","journal-title":"Eur Neuropsychopharmacol"},{"key":"2020122903594710500_CIT0039","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.biopsych.2011.04.013","article-title":"Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects","volume":"70","author":"Miller","year":"2011","journal-title":"Biol Psychiatry"},{"key":"2020122903594710500_CIT0040","doi-asserted-by":"crossref","first-page":"135","DOI":"10.4103\/ipj.ipj_30_15","article-title":"Negative symptoms in schizophrenia","volume":"25","author":"Mitra","year":"2016","journal-title":"Ind Psychiatry J"},{"key":"2020122903594710500_CIT0041","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0306-4522(03)00099-X","article-title":"Implication of brain-derived neurotrophic factor in the release of dopamine and dopamine-related behaviors induced by methamphetamine","volume":"119","author":"Narita","year":"2003","journal-title":"Neuroscience"},{"key":"2020122903594710500_CIT0042","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.bbadis.2014.10.006","article-title":"Roles of resveratrol and other grape-derived polyphenols in Alzheimer\u2019s disease prevention and treatment","volume":"1852","author":"Pasinetti","year":"2015","journal-title":"Biochim Biophys Acta"},{"key":"2020122903594710500_CIT0043","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1080\/1028415X.2017.1284361","article-title":"Current evidence for AMPK activation involvement on resveratrol-induced neuroprotection in cerebral ischemia","volume":"21","author":"Pineda-Ram\u00edrez","year":"2018","journal-title":"Nutr Neurosci"},{"key":"2020122903594710500_CIT0044","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.biopsych.2007.09.024","article-title":"Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review","volume":"63","author":"Potvin","year":"2008","journal-title":"Biol Psychiatry"},{"key":"2020122903594710500_CIT0045","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.tiv.2013.12.021","article-title":"Oxidative stress mediated by NMDA, AMPA\/KA channels in acute hippocampal slices: neuroprotective effect of resveratrol","volume":"28","author":"Quincozes-Santos","year":"2014","journal-title":"Toxicol in Vitro"},{"key":"2020122903594710500_CIT0046","doi-asserted-by":"crossref","first-page":"218","DOI":"10.3389\/fnagi.2014.00218","article-title":"Neuroprotective effects of resveratrol in Alzheimer disease pathology","volume":"6","author":"Rege","year":"2014","journal-title":"Front Aging Neurosci"},{"key":"2020122903594710500_CIT0047","doi-asserted-by":"crossref","first-page":"419092","DOI":"10.1155\/2013\/419092","article-title":"Resveratrol protects the brain of obese mice from oxidative damage","volume":"2013","author":"Rege","year":"2013","journal-title":"Oxid Med Cell Longev"},{"key":"2020122903594710500_CIT0049","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1586\/ern.10.191","article-title":"Schizophrenia as a disorder of too little dopamine: implications for symptoms and treatment","volume":"11","author":"Remington","year":"2011","journal-title":"Expert Rev Neurother"},{"key":"2020122903594710500_CIT0050","doi-asserted-by":"crossref","DOI":"10.1002\/hup.2583","article-title":"Cilostazol adjunctive therapy in treatment of negative symptoms in chronic schizophrenia: randomized, double-blind, placebo-controlled study","volume":"32","author":"Rezaei","year":"2017","journal-title":"Hum Psychopharmacol"},{"key":"2020122903594710500_CIT0051","doi-asserted-by":"crossref","first-page":"e141","DOI":"10.1371\/journal.pmed.0020141","article-title":"A systematic review of the prevalence of schizophrenia","volume":"2","author":"Saha","year":"2005","journal-title":"Plos Med"},{"key":"2020122903594710500_CIT0052","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.mrrev.2007.08.004","article-title":"Resveratrol and its analogs: defense against cancer, coronary disease and neurodegenerative maladies or just a fad?","volume":"658","author":"Saiko","year":"2008","journal-title":"Mutat Res"},{"key":"2020122903594710500_CIT0053","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jad.2013.11.003","article-title":"A randomized, double-blind, clinical trial comparing the efficacy and safety of Crocus sativus L. with fluoxetine for improving mild to moderate depression in post percutaneous coronary intervention patients","volume":"155","author":"Shahmansouri","year":"2014","journal-title":"J Affect Disord"},{"key":"2020122903594710500_CIT0054","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.neulet.2005.02.054","article-title":"Decreased BDNF in serum of patients with chronic schizophrenia on long-term treatment with antipsychotics","volume":"382","author":"Tan","year":"2005","journal-title":"Neurosci Lett"},{"key":"2020122903594710500_CIT0055","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1212\/WNL.0000000000002035","article-title":"A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease","volume":"85","author":"Turner","year":"2015","journal-title":"Neurology"},{"key":"2020122903594710500_CIT0056","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.schres.2014.03.005","article-title":"Cytokine function in medication-naive first episode psychosis: a systematic review and meta-analysis","volume":"155","author":"Upthegrove","year":"2014","journal-title":"Schizophr Res"},{"key":"2020122903594710500_CIT0057","doi-asserted-by":"crossref","first-page":"7862","DOI":"10.1523\/JNEUROSCI.0385-14.2014","article-title":"Effects of resveratrol on memory performance, hippocampal functional connectivity, and glucose metabolism in healthy older adults","volume":"34","author":"Witte","year":"2014","journal-title":"J Neurosci"},{"key":"2020122903594710500_CIT0058","doi-asserted-by":"crossref","first-page":"937605","DOI":"10.1155\/2012\/937605","article-title":"Resveratrol produces neurotrophic effects on cultured dopaminergic neurons through prompting astroglial BDNF and GDNF release","volume":"2012","author":"Zhang","year":"2012","journal-title":"Evid Based Complement Alternat Med"},{"key":"2020122903594710500_CIT0059","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3389\/fpsyt.2016.00159","article-title":"Resveratrol supplementation did not improve cognition in patients with schizophrenia: results from a randomized clinical trial","volume":"7","author":"Zortea","year":"2016","journal-title":"Front Psychiatry"}],"container-title":["International Journal of Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ijnp\/advance-article-pdf\/doi\/10.1093\/ijnp\/pyaa006\/34635780\/pyaa006.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ijnp\/article-pdf\/23\/12\/775\/35175770\/pyaa006.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ijnp\/article-pdf\/23\/12\/775\/35175770\/pyaa006.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,29]],"date-time":"2020-12-29T09:02:10Z","timestamp":1609232530000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ijnp\/article\/23\/12\/775\/6015733"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,1]]},"references-count":58,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12,29]]}},"URL":"https:\/\/doi.org\/10.1093\/ijnp\/pyaa006","relation":{},"ISSN":["1461-1457","1469-5111"],"issn-type":[{"value":"1461-1457","type":"print"},{"value":"1469-5111","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12,1]]},"published":{"date-parts":[[2020,12,1]]}}}